Menon’s Molecular Mirror (M²) is the only technology of its kind that provides flexibility in assay diagnostics on a single platform.  Over competing technologies, M² provides the following advantages:

• 100% specificity
• 4x faster
• 5x more sensitive
• 50% less expensive by leveraging existing equipment

• Tested funded by United States Department of Homeland Security (DHS) and Defense Threat Reduction Agency (DTRA) were conducted against a panel of 20 biothreat agents.  In blind tests, the Menon technology was the only contender capable of 100% detection with zero false-alarms and was recognized as the only confirmer unit by DHS and DTRA  Boston Subway System to be Used to Test New Sensors for Biological Agents.
• Third party clinical validation studies were completed at University of Southern California (USC) for detection of toxigenic Clostridium difficile in clinical stool specimens, funded by a major molecular diagnostics company.  Cross-reactivity tests demonstrated 100% specificity.  Results were presented at the ECCMID conference held in Copenhagen, Denmark Application of a novel nuclear magnetic resonance platform to detect C. difficile.
• Validated sensitivity and specificity for Vibrio spp. food safety applications in India, Mexico, Thailand, Indonesia.  Early detection of this pathogen in shrimp tissue enables shrimp farmers to take action in their shrimp ponds to avoid devastating economic losses due to Early Mortality Syndrome.
• Third party validation studies were conducted for Salmonella detection in tuna at Bumble Bee seafood.  Rapid detection in tuna processing is vital to human food safety. The Menon assay was capable of detection of Salmonella in tuna in a fraction of the time required for traditional FDA approved methods.
• Tests were completed for TB detection with University of California San Diego to demonstrate the assay’s capability in difficult matrices such as sputum.
• Tests were completed for Vibrio parahaemolyticus detection in shrimp tissue with University of Arizona.